Emergent BioSolutions Notified by HHS That Its Proposal to Provide 25 Million Doses of Its Recombinant Anthrax Vaccine Is Technically Acceptable and Within the Competitive Range.

Business Wire › September 12, 2008

Linked as:

Extract

Emergent BioSolutions Notified by HHS That Its Proposal to Provide 25 Million Doses of Its Recombinant Anthrax Vaccine Is Technically Acceptable and Within the Competitive Range.

ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Department of Health and Human Services (HHS) has informed the company that its proposal to provide a recombinant protective antigen anthrax vaccine (rPA) is technically acceptable and within th...

See the full content of this document